nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Ibandronate—Shock—Prednisolone—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Ibandronate—Hypertension—Triamcinolone—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Ibandronate—Hypertension—Methylprednisolone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Ibandronate—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Ibandronate—Myalgia—Triamcinolone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Ibandronate—Myalgia—Methylprednisolone—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Ibandronate—Arthralgia—Methylprednisolone—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Ibandronate—Eye disorder—Prednisone—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Ibandronate—Anxiety—Methylprednisolone—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Ibandronate—Infestation—Methotrexate—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Ibandronate—Depression—Methotrexate—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Ibandronate—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Ibandronate—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Ibandronate—Discomfort—Triamcinolone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Ibandronate—Discomfort—Methylprednisolone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Ibandronate—Dry mouth—Triamcinolone—psoriatic arthritis	0.00142	0.00142	CcSEcCtD
Ibandronate—Renal failure—Methotrexate—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Ibandronate—Angioedema—Dexamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Ibandronate—Angioedema—Betamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Ibandronate—Angiopathy—Prednisone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Ibandronate—Immune system disorder—Prednisone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Ibandronate—Malaise—Betamethasone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Ibandronate—Malaise—Dexamethasone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Ibandronate—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Ibandronate—Vertigo—Dexamethasone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Ibandronate—Vertigo—Betamethasone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Ibandronate—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Ibandronate—Infection—Triamcinolone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Ibandronate—Sweating—Methotrexate—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Ibandronate—Infection—Methylprednisolone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Ibandronate—Shock—Triamcinolone—psoriatic arthritis	0.00137	0.00137	CcSEcCtD
Ibandronate—Insomnia—Prednisolone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Ibandronate—Alopecia—Prednisone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Ibandronate—Shock—Methylprednisolone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Ibandronate—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Ibandronate—Paraesthesia—Prednisolone—psoriatic arthritis	0.00135	0.00135	CcSEcCtD
Ibandronate—Mental disorder—Prednisone—psoriatic arthritis	0.00135	0.00135	CcSEcCtD
Ibandronate—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Ibandronate—Malnutrition—Prednisone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Ibandronate—Erythema—Prednisone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Ibandronate—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Ibandronate—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Ibandronate—Hypertension—Betamethasone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Ibandronate—Hypertension—Dexamethasone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Ibandronate—Myalgia—Dexamethasone—psoriatic arthritis	0.00131	0.00131	CcSEcCtD
Ibandronate—Myalgia—Betamethasone—psoriatic arthritis	0.00131	0.00131	CcSEcCtD
Ibandronate—Anxiety—Betamethasone—psoriatic arthritis	0.00131	0.00131	CcSEcCtD
Ibandronate—Anxiety—Dexamethasone—psoriatic arthritis	0.00131	0.00131	CcSEcCtD
Ibandronate—Discomfort—Dexamethasone—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Ibandronate—Discomfort—Betamethasone—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Ibandronate—Pain—Prednisolone—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—psoriatic arthritis	0.00128	0.00128	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Ibandronate—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Ibandronate—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Ibandronate—Insomnia—Triamcinolone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Ibandronate—Insomnia—Methylprednisolone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Ibandronate—Infection—Dexamethasone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Ibandronate—Infection—Betamethasone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Ibandronate—Ill-defined disorder—Prednisone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Ibandronate—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Ibandronate—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Ibandronate—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Ibandronate—Anaemia—Prednisone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Ibandronate—Shock—Betamethasone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Ibandronate—Shock—Dexamethasone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Ibandronate—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Ibandronate—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Ibandronate—Angioedema—Prednisone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Ibandronate—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Ibandronate—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Ibandronate—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Ibandronate—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Ibandronate—Malaise—Prednisone—psoriatic arthritis	0.00121	0.00121	CcSEcCtD
Ibandronate—Vertigo—Prednisone—psoriatic arthritis	0.00121	0.00121	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—psoriatic arthritis	0.00121	0.00121	CcSEcCtD
Ibandronate—Urticaria—Prednisolone—psoriatic arthritis	0.0012	0.0012	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—psoriatic arthritis	0.0012	0.0012	CcSEcCtD
Ibandronate—Fatigue—Triamcinolone—psoriatic arthritis	0.0012	0.0012	CcSEcCtD
Ibandronate—Fatigue—Methylprednisolone—psoriatic arthritis	0.00119	0.00119	CcSEcCtD
Ibandronate—Pain—Triamcinolone—psoriatic arthritis	0.00119	0.00119	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Ibandronate—Hypertension—Prednisone—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Ibandronate—Chills—Methotrexate—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00115	0.00115	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00115	0.00115	CcSEcCtD
Ibandronate—Arthralgia—Prednisone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Myalgia—Prednisone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Anxiety—Prednisone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Insomnia—Betamethasone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Insomnia—Dexamethasone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Ibandronate—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Ibandronate—Paraesthesia—Betamethasone—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Ibandronate—Discomfort—Prednisone—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—psoriatic arthritis	0.00112	0.00112	CcSEcCtD
Ibandronate—Erythema—Methotrexate—psoriatic arthritis	0.00112	0.00112	CcSEcCtD
Ibandronate—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Ibandronate—Dyspepsia—Betamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Ibandronate—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Ibandronate—Urticaria—Triamcinolone—psoriatic arthritis	0.0011	0.0011	CcSEcCtD
Ibandronate—Urticaria—Methylprednisolone—psoriatic arthritis	0.0011	0.0011	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—psoriatic arthritis	0.0011	0.0011	CcSEcCtD
Ibandronate—Body temperature increased—Triamcinolone—psoriatic arthritis	0.0011	0.0011	CcSEcCtD
Ibandronate—Anaphylactic shock—Prednisone—psoriatic arthritis	0.0011	0.0011	CcSEcCtD
Ibandronate—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Decreased appetite—Betamethasone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Infection—Prednisone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Back pain—Methotrexate—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Fatigue—Dexamethasone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Fatigue—Betamethasone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Ibandronate—Shock—Prednisone—psoriatic arthritis	0.00108	0.00108	CcSEcCtD
Ibandronate—Pain—Dexamethasone—psoriatic arthritis	0.00108	0.00108	CcSEcCtD
Ibandronate—Pain—Betamethasone—psoriatic arthritis	0.00108	0.00108	CcSEcCtD
Ibandronate—Nervous system disorder—Prednisone—psoriatic arthritis	0.00108	0.00108	CcSEcCtD
Ibandronate—Skin disorder—Prednisone—psoriatic arthritis	0.00107	0.00107	CcSEcCtD
Ibandronate—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00106	0.00106	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.00104	0.00104	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—psoriatic arthritis	0.00104	0.00104	CcSEcCtD
Ibandronate—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00104	0.00104	CcSEcCtD
Ibandronate—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00104	0.00104	CcSEcCtD
Ibandronate—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00103	0.00103	CcSEcCtD
Ibandronate—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00103	0.00103	CcSEcCtD
Ibandronate—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Ibandronate—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Ibandronate—Malaise—Methotrexate—psoriatic arthritis	0.00101	0.00101	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—psoriatic arthritis	0.00101	0.00101	CcSEcCtD
Ibandronate—Urticaria—Betamethasone—psoriatic arthritis	0.001	0.001	CcSEcCtD
Ibandronate—Urticaria—Dexamethasone—psoriatic arthritis	0.001	0.001	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000999	0.000999	CcSEcCtD
Ibandronate—Dizziness—Prednisolone—psoriatic arthritis	0.000998	0.000998	CcSEcCtD
Ibandronate—Asthenia—Triamcinolone—psoriatic arthritis	0.000996	0.000996	CcSEcCtD
Ibandronate—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000995	0.000995	CcSEcCtD
Ibandronate—Body temperature increased—Betamethasone—psoriatic arthritis	0.000995	0.000995	CcSEcCtD
Ibandronate—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000995	0.000995	CcSEcCtD
Ibandronate—Abdominal pain—Betamethasone—psoriatic arthritis	0.000995	0.000995	CcSEcCtD
Ibandronate—Asthenia—Methylprednisolone—psoriatic arthritis	0.000993	0.000993	CcSEcCtD
Ibandronate—Insomnia—Prednisone—psoriatic arthritis	0.000992	0.000992	CcSEcCtD
Ibandronate—Paraesthesia—Prednisone—psoriatic arthritis	0.000985	0.000985	CcSEcCtD
Ibandronate—Pruritus—Triamcinolone—psoriatic arthritis	0.000982	0.000982	CcSEcCtD
Ibandronate—Pruritus—Methylprednisolone—psoriatic arthritis	0.00098	0.00098	CcSEcCtD
Ibandronate—Dyspepsia—Prednisone—psoriatic arthritis	0.000965	0.000965	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—psoriatic arthritis	0.000956	0.000956	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—psoriatic arthritis	0.000956	0.000956	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—psoriatic arthritis	0.000956	0.000956	CcSEcCtD
Ibandronate—Decreased appetite—Prednisone—psoriatic arthritis	0.000953	0.000953	CcSEcCtD
Ibandronate—Rash—Prednisolone—psoriatic arthritis	0.000951	0.000951	CcSEcCtD
Ibandronate—Dermatitis—Prednisolone—psoriatic arthritis	0.000951	0.000951	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000949	0.000949	CcSEcCtD
Ibandronate—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000947	0.000947	CcSEcCtD
Ibandronate—Fatigue—Prednisone—psoriatic arthritis	0.000945	0.000945	CcSEcCtD
Ibandronate—Headache—Prednisolone—psoriatic arthritis	0.000945	0.000945	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—psoriatic arthritis	0.000944	0.000944	CcSEcCtD
Ibandronate—Constipation—Prednisone—psoriatic arthritis	0.000938	0.000938	CcSEcCtD
Ibandronate—Dizziness—Triamcinolone—psoriatic arthritis	0.000918	0.000918	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000916	0.000916	CcSEcCtD
Ibandronate—Dizziness—Methylprednisolone—psoriatic arthritis	0.000916	0.000916	CcSEcCtD
Ibandronate—Infection—Methotrexate—psoriatic arthritis	0.00091	0.00091	CcSEcCtD
Ibandronate—Feeling abnormal—Prednisone—psoriatic arthritis	0.000904	0.000904	CcSEcCtD
Ibandronate—Asthenia—Betamethasone—psoriatic arthritis	0.000903	0.000903	CcSEcCtD
Ibandronate—Asthenia—Dexamethasone—psoriatic arthritis	0.000903	0.000903	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000899	0.000899	CcSEcCtD
Ibandronate—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000897	0.000897	CcSEcCtD
Ibandronate—Nausea—Prednisolone—psoriatic arthritis	0.000896	0.000896	CcSEcCtD
Ibandronate—Pruritus—Dexamethasone—psoriatic arthritis	0.000891	0.000891	CcSEcCtD
Ibandronate—Pruritus—Betamethasone—psoriatic arthritis	0.000891	0.000891	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—psoriatic arthritis	0.00089	0.00089	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000886	0.000886	CcSEcCtD
Ibandronate—Vomiting—Triamcinolone—psoriatic arthritis	0.000882	0.000882	CcSEcCtD
Ibandronate—Vomiting—Methylprednisolone—psoriatic arthritis	0.00088	0.00088	CcSEcCtD
Ibandronate—Rash—Triamcinolone—psoriatic arthritis	0.000875	0.000875	CcSEcCtD
Ibandronate—Dermatitis—Triamcinolone—psoriatic arthritis	0.000874	0.000874	CcSEcCtD
Ibandronate—Rash—Methylprednisolone—psoriatic arthritis	0.000873	0.000873	CcSEcCtD
Ibandronate—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000872	0.000872	CcSEcCtD
Ibandronate—Urticaria—Prednisone—psoriatic arthritis	0.000871	0.000871	CcSEcCtD
Ibandronate—Headache—Triamcinolone—psoriatic arthritis	0.000869	0.000869	CcSEcCtD
Ibandronate—Headache—Methylprednisolone—psoriatic arthritis	0.000867	0.000867	CcSEcCtD
Ibandronate—Abdominal pain—Prednisone—psoriatic arthritis	0.000867	0.000867	CcSEcCtD
Ibandronate—Body temperature increased—Prednisone—psoriatic arthritis	0.000867	0.000867	CcSEcCtD
Ibandronate—Diarrhoea—Betamethasone—psoriatic arthritis	0.000862	0.000862	CcSEcCtD
Ibandronate—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000862	0.000862	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000835	0.000835	CcSEcCtD
Ibandronate—Dizziness—Betamethasone—psoriatic arthritis	0.000833	0.000833	CcSEcCtD
Ibandronate—Dizziness—Dexamethasone—psoriatic arthritis	0.000833	0.000833	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—psoriatic arthritis	0.000829	0.000829	CcSEcCtD
Ibandronate—Nausea—Triamcinolone—psoriatic arthritis	0.000824	0.000824	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—psoriatic arthritis	0.000823	0.000823	CcSEcCtD
Ibandronate—Nausea—Methylprednisolone—psoriatic arthritis	0.000822	0.000822	CcSEcCtD
Ibandronate—Hypersensitivity—Prednisone—psoriatic arthritis	0.000808	0.000808	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—psoriatic arthritis	0.000807	0.000807	CcSEcCtD
Ibandronate—Vomiting—Dexamethasone—psoriatic arthritis	0.000801	0.000801	CcSEcCtD
Ibandronate—Vomiting—Betamethasone—psoriatic arthritis	0.000801	0.000801	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—psoriatic arthritis	0.000797	0.000797	CcSEcCtD
Ibandronate—Rash—Dexamethasone—psoriatic arthritis	0.000794	0.000794	CcSEcCtD
Ibandronate—Rash—Betamethasone—psoriatic arthritis	0.000794	0.000794	CcSEcCtD
Ibandronate—Dermatitis—Betamethasone—psoriatic arthritis	0.000793	0.000793	CcSEcCtD
Ibandronate—Dermatitis—Dexamethasone—psoriatic arthritis	0.000793	0.000793	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000791	0.000791	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—psoriatic arthritis	0.00079	0.00079	CcSEcCtD
Ibandronate—Headache—Dexamethasone—psoriatic arthritis	0.000789	0.000789	CcSEcCtD
Ibandronate—Headache—Betamethasone—psoriatic arthritis	0.000789	0.000789	CcSEcCtD
Ibandronate—Asthenia—Prednisone—psoriatic arthritis	0.000787	0.000787	CcSEcCtD
Ibandronate—Pain—Methotrexate—psoriatic arthritis	0.000784	0.000784	CcSEcCtD
Ibandronate—Pruritus—Prednisone—psoriatic arthritis	0.000776	0.000776	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000755	0.000755	CcSEcCtD
Ibandronate—Diarrhoea—Prednisone—psoriatic arthritis	0.00075	0.00075	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000749	0.000749	CcSEcCtD
Ibandronate—Nausea—Dexamethasone—psoriatic arthritis	0.000748	0.000748	CcSEcCtD
Ibandronate—Nausea—Betamethasone—psoriatic arthritis	0.000748	0.000748	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—psoriatic arthritis	0.000728	0.000728	CcSEcCtD
Ibandronate—Dizziness—Prednisone—psoriatic arthritis	0.000725	0.000725	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—psoriatic arthritis	0.000724	0.000724	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—psoriatic arthritis	0.000724	0.000724	CcSEcCtD
Ibandronate—Vomiting—Prednisone—psoriatic arthritis	0.000697	0.000697	CcSEcCtD
Ibandronate—Rash—Prednisone—psoriatic arthritis	0.000691	0.000691	CcSEcCtD
Ibandronate—Dermatitis—Prednisone—psoriatic arthritis	0.000691	0.000691	CcSEcCtD
Ibandronate—Headache—Prednisone—psoriatic arthritis	0.000687	0.000687	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000675	0.000675	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—psoriatic arthritis	0.000657	0.000657	CcSEcCtD
Ibandronate—Nausea—Prednisone—psoriatic arthritis	0.000651	0.000651	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—psoriatic arthritis	0.000648	0.000648	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—psoriatic arthritis	0.000627	0.000627	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—psoriatic arthritis	0.000606	0.000606	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—psoriatic arthritis	0.000583	0.000583	CcSEcCtD
Ibandronate—Rash—Methotrexate—psoriatic arthritis	0.000578	0.000578	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—psoriatic arthritis	0.000577	0.000577	CcSEcCtD
Ibandronate—Headache—Methotrexate—psoriatic arthritis	0.000574	0.000574	CcSEcCtD
Ibandronate—Nausea—Methotrexate—psoriatic arthritis	0.000544	0.000544	CcSEcCtD
